CapsoVision, Inc. (CV)
NASDAQ:CV
CV Stock Chart & Stats
$13.23
--
Market closed
$13.23
--
Day’s Range― - ―
52-Week Range$3.43 - $15.37
Previous CloseN/A
VolumeN/A
Average Volume (3M)45.47K
Market Cap
$311.49M
Enterprise Value$312.73M
Total Cash (Recent Filing)$10.11M
Total Debt (Recent Filing)$887.00K
Price to Earnings (P/E)―
Beta-1.52
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding49,838,210
10 Day Avg. Volume21,973
30 Day Avg. Volume45,470
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)197.96
Price to Sales (P/S)193.67
P/FCF Ratio-114.36
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue23.07
Enterprise Value/Gross Profit43.60
Enterprise Value/Ebitda-12.53
Forecast
1Y Price Target
$10.50Price Target Upside-20.63% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.49
Revenue Forecast (FY)$19.07M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & MarginsSustained double-digit revenue growth and stable mid-50s gross margins indicate improving product adoption and unit economics. Together with operating-line improvement toward breakeven in 2025, these trends provide a durable foundation for scaling profitably if operating leverage and cost control continue.
Regulatory/Product AdvancementRedirecting resources to a second-generation CapsoCam Colon with expanded pivotal enrollment (>500 patients to date) and a planned 510(k) strengthens the company’s regulatory positioning. A larger, better-designed submission improves long-term approval odds and sustainable market access despite delaying near-term commercialization.
Strategic Supply PartnershipSecuring upgraded image sensors via an amended Canon development agreement preserves supply terms while improving technical specs. This durable supplier relationship reduces component risk, enhances product differentiation in imaging quality, and supports clinical/regulatory success and long-term competitive positioning.
Bears Say
Persistent Cash BurnMaterial negative operating and free cash flows across multiple years show the business currently consumes capital faster than it generates it. This chronic cash burn creates sustained financing dependence, increases dilution risk, and constrains strategic flexibility unless a durable shift to positive FCF occurs.
Fragile Capital BaseAlthough reported debt is low, accumulated losses produced deeply negative equity in prior years and highly variable returns. That history reflects a fragile capital base that can require future equity raises, diluting shareholders and limiting the company’s ability to absorb clinical or commercial setbacks long-term.
Regulatory Setback & Longer TimelinesRegulatory questions forced halting the first-generation pathway and expanding the pivotal study to roughly 800 patients for a second-gen device. This materially extends development timelines, increases clinical costs, and concentrates program risk on successful larger trials, delaying sustainable commercial revenue.
CapsoVision, Inc. News
CV FAQ
What was CapsoVision, Inc.’s price range in the past 12 months?
CapsoVision, Inc. lowest stock price was $3.43 and its highest was $15.37 in the past 12 months.
What is CapsoVision, Inc.’s market cap?
CapsoVision, Inc.’s market cap is $311.49M.
When is CapsoVision, Inc.’s upcoming earnings report date?
CapsoVision, Inc.’s upcoming earnings report date is Aug 13, 2026 which is in 120 days.
How were CapsoVision, Inc.’s earnings last quarter?
CapsoVision, Inc. released its earnings results on Mar 26, 2026. The company reported -$0.155 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.01.
Is CapsoVision, Inc. overvalued?
According to Wall Street analysts CapsoVision, Inc.’s price is currently Overvalued.
Does CapsoVision, Inc. pay dividends?
CapsoVision, Inc. does not currently pay dividends.
What is CapsoVision, Inc.’s EPS estimate?
CapsoVision, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CapsoVision, Inc. have?
CapsoVision, Inc. has 49,838,210 shares outstanding.
What happened to CapsoVision, Inc.’s price movement after its last earnings report?
CapsoVision, Inc. reported an EPS of -$0.155 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went down -0.266%.
Which hedge fund is a major shareholder of CapsoVision, Inc.?
Currently, no hedge funds are holding shares in CV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CapsoVision, Inc. Stock Smart Score
Company Description
CapsoVision, Inc.
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
CV Earnings Call
Q4 2026
0:00 / 0:00
CV Stock 12 Month Forecast
Average Price Target
$10.50
▼(-20.63% Downside)
Technical Analysis
Ownership Overview
2.75% Insiders
0.51% Mutual Funds
0.02% Other Institutional Investors
94.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---